Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
June 27 2024 - 3:00AM
Release Therapeutics Announces New CEO to Drive Best-in-Class CNS
Innovation
Release Therapeutics (‘Release Tx’ or ‘the Company’), a
privately-held, Swiss BioMedTech company, announced today the
appointment of Thomas Mehrling, MD, PhD, as CEO. The appointment
follows the recent strategic pivot of Release Tx (formerly,
‘MaxiVax’) towards treating genetic disorders of the central
nervous system (CNS) with a best-in-class cell macroencapsulation
technology as an alternative to gene therapy.1
With over 25 years’ experience in multinational pharma
companies, including Takeda, Mundipharma International and
Hoffmann-La Roche, Dr. Mehrling is an expert in developing novel
oncology compounds from bench to bedside. During his tenure at
MundiPharma International (2003–2013), he oversaw the clinical
development, registration and launch of two major products in
Europe, Depocyte® and Levact® (Ribomustin® and Treanda®). Dr.
Mehrling received his PhD in Pharmacology and MD from the
University of Frankfurt, where he previously spent 13 years working
on research projects in cardiology and oncology.
Release Tx is developing a proprietary technology capable of
delivering highly potent therapeutic proteins beyond the
blood-brain barrier (BBB) for the long-term treatment of CNS
disorders. Consisting of an implantable macroencapsulation device
and a human myoblast cell line that can be genetically modified to
produce diverse proteins, this technology is the first of its kind
to be designed for cell macroencapsulation in humans.2 The lead
programme of Release Tx focuses on treating Metachromatic
Leukodystrophy (MLD), a rare genetic CNS disorder typically
affecting young children.
Release Tx’s Chairman, Ksenija Pavletic, said, “We’re thrilled
to have Dr. Mehrling on board to lead Release Therapeutics on its
new mission. The remarkable progress we’ve made with our technology
now offers significant advantages over gene therapy for the
treatment of CNS diseases, bringing hope to patients and their
families around the world.”
Thomas Mehrling, MD, PhD, said ‘Release Therapeutics’ technology
is a game-changer in getting therapeutic proteins where they are
needed most. I am looking forward to driving the company towards
this goal.’
References
(1) https://www.release-tx.com/post/treating-genetic-disorders-of-the-cns-without-gene-therapy-or-what-we-ve-been-up-to-here-at-release(2) https://www.release-tx.com/post/release-therapeutics-publishes-cutting-edge-research-in-cell-press
About Release Therapeutics
Headquartered in Geneva, Switzerland, Release Therapeutics is a
privately-held, BioMedTech company developing the first cell
macroencapsulation technology designed to deliver potent
therapeutic proteins beyond the human blood-brain barrier. The
Company’s proprietary technology integrates an implantable
macroencapsulation device with an immortalised myoblast cell line
capable of producing a broad range of proteins for long-term
delivery to the CNS. Innovating at the nexus of biotech and
MedTech, Release Therapeutics is on a mission to treat genetic
diseases of the CNS without gene therapy. The company’s lead
programme is in preclinical development for the treatment of
Metachromatic Leukodystrophy (MLD), a rare genetic disorder that
leads to progressive loss of myelin and typically affects young
children.
For more information, please visit our website:
https://www.release-tx.com/
Contacts
Release Therapeutics SAcontact@release-tx.com
Manage Mind Greece (for Release Therapeutics)Jessica
KourniaktisPhone: (+30)6932254679Email:
jkourniakti@managemind.ch